SUWANEE, GA, Dec. 12, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB:
SNWV) an emerging medical technology company focused on the development and commercialization of noninvasive,
biological response activating devices in regenerative medicine, reflects upon a summary of patent issuances for year 2018.
It was a productive year as the company added two new US patents and two European patents with 7 designated countries, as follows:
· U.S. patent number US 10,053,376 entitled “Acoustic Pressure Shock Wave Devices and
Methods for Fluids Processing” was issued on August 28, 2018 and has an effective life through December 2036. The patent
includes twenty claims relating to the use of shockwaves for removing particulate matter from contaminated waters.
· U.S. patent number US 10,058,340 entitled “Extracorporeal Pressure Shock
Wave Devices with Multiple Reflectors and Methods for Using These Devices” was issued on August 28, 2018 and has an effective life
through November 2032. The patent includes twenty claims relating to the use of extracorporeal shockwaves, generated from
multiple reflectors for cardiovascular applications, orthopedic afflictions, infection elimination, and stem cells stimulation,
proliferation and differentiation.
· European patent number EP 2,984,280 entitled “Apparatuses and Methods for
Generating Shock Waves for Use in the Energy Industry” was issued on August 8, 2018 and has an effective life through April 2034,
with designated national issuances in Great Britain and France. The patent includes fifteen claims relating to the use of
shockwaves, generated with laser systems, for hydraulic fracturing of rock formations, which can be employed in both secondary and
tertiary oil recovery.
· European patent number EP 3,117,784 entitled “Usage of Intracorporeal
Pressure Shock Waves in Medicine” is designated to be issued on December 26, 2018 and has an effective life through to July 2030,
with designated national issuances in Great Britain, Germany, France, Italy, and Spain. The patent includes fifteen claims
relating to the use of intracorporeal shockwaves in medical field.
With the aforementioned patent additions, SANUWAVE, Inc. and its wholly owned subsidiary SANUWAVE Health Inc. have
a total of 65 patents issued or pending in the field of shockwaves used in medical and non-medical applications.
Shri Parikh, President of SANUWAVE, stated, “We are pleased at the depth and prolific nature of our innovation
activities. In 2018 we added nine new patents in the United States and parts of Europe that align with, and protect, our
long-term innovations strategy. With many of our newer patent applications, SANUWAVE is also positioning favorable
intellectual property protection around the world with countries in South America, Middle East, and Asia.”
Kevin A. Richardson, II, Chairman of the Board of Directors of SANUWAVE, also commented, stating, “We have a
continuous commitment to innovate and protect SANUWAVE shockwave technology. Our new patents will reinforce the protection
for new medical systems that can be used in a broad spectrum of applications, offer increased efficiency, and maximize the value of
our pressure shockwave technology used for wound care and orthopedics. SANUWAVE’s new applications extend beyond regenerative
medicine and support SANUWAVE’s long term strategy to maximize the value of our shockwave technology in both medical and
non-medical fields.”
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company initially focused on the development and
commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin,
musculoskeletal tissue, and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product
candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement,
which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound
healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market,
dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft
tissue in Canada, Australia and New Zealand. In the U.S., dermaPACE® is currently under the FDA’s Premarket Approval (PMA)
review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services
its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in
chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved
OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the
utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are
license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and
industrial markets.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of
1995, such as statements relating to financial results and plans for future business development activities and are thus
prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief
or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking
statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s
ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key
risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the
regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development
activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors
discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no
obligation to update any forward-looking statement.
For additional information about the Company, visit www.sanuwave.com.
Contact: Millennium Park Capital, LLC Christopher Wynne 312-724-7845 cwynne@mparkcm.com SANUWAVE Health, Inc. Kevin Richardson II Chairman of the Board 978-922-2447 investorrelations@sanuwave.com
